SAVA

Cassava Sciences, Inc. is a clinical-stage biotechnology firm headquartered in Austin, Texas, focused on developing breakthrough therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its leading candidate, simufilam, is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. By targeting significant unmet medical needs in neurology, Cassava aims to revolutionize the treatment paradigm for neurodegenerative disorders, setting a foundation for improving patient outcomes and quality of life while enhancing its strategic position within the biotechnology sector.